Tequin

TequinTequin, one of the brand names for the pharmaceutical product Gatifloxacin, was introduced to the U.S. market by Bristol-Myers Squibb in 1999. The drug, an antibiotic, was prescribed primarily for the treatment of respiratory tract infections.

In 2006, a report in the New England Journal of Medicine alleged that Tequin had been found to put users at an elevated risk for dysglycemia, a blood sugar metabolism disorder that may manifest as either hyperglycemia (high blood sugar) or hypoglycemia (low blood sugar). Initially, Bristol-Myers Squibb notified health care providers that product warnings would be enhanced. However, the company subsequently opted to terminate the manufacture of Tequin. The product is now available only as treatment for eye conditions, in the form of an eye drop.

If you experienced side effects after being prescribed Tequin, GetLegal has the tools and resources to help you find skilled legal representation to protect your rights. Visit our attorney directory, look for your geographic location and find the best lawyer for your situation.

    Latest Article

      GETLEGAL®ATTORNEY DIRECTORY

      Find Leading Attorneys in Your Area

          NEED PROFESSIONAL HELP?

          Talk to an Attorney

          How It Works

          • Briefly tell us about your case
          • Provide your contact information
          • Choose attorneys to contact you

          ABOUT GETLEGAL

          Our mission at GetLegal is to develop a family of sites that constitute the most useful, informative, reliable and exciting collection of legal resources on the web. We are constantly working to expand and improve many resources we offer to legal professionals and the public.

          Contact Us : 877-359-7077

          RECENT TWEETS

          NEWSLETTER SIGN-UP

          By submitting information to this site, you give permission to GetLegal, or a partner of GetLegal, to contact you by email.

          Advertise With Us

          © 2008-2021 LawConnect, Inc. All rights reserved. Sitemap | Copyright/DMCA Policy | Privacy Policy | Terms of Use | Disclosures/Disclaimers